Company Valuation: Alaunos Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2026 2027 2028
Market Cap 1 234 155.4 16.98 4.065 - -
Change - -33.56% -89.08% - - -
Enterprise Value (EV) 234 155.4 16.98 4.065 4.065 4.065
Change - -33.56% -89.08% - 0% 0%
P/E -2.95x -3.82x -0.48x -8x -0.71x -0.33x
PBR - - - - - -
PEG - 0.1x 0x - -0x -0x
Capitalization / Revenue 588x 53.2x 3,396x - - -
EV / Revenue 0x 0x 0x - - -
EV / EBITDA - - - - - -
EV / EBIT -0x -0x -0x -0.2x -0.07x -0.03x
EV / FCF -0x - - -0.24x -0.08x -0.03x
FCF Yield -27.7% - - -418% -1,279% -2,878%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -55.5 -25.5 -22 -0.2 -2.25 -4.8
Distribution rate - - - - - -
Net sales 1 0.398 2.922 0.005 - - -
EBITDA - - - - - -
EBIT 1 -73.31 -35.1 -34.27 -20 -60 -130
Net income 1 -78.75 -37.73 -35.14 -17 -45 -120
Net Debt - - - - - -
Reference price 2 163.500 97.365 10.605 1.600 1.600 1.600
Nbr of stocks (in thousands) 1,431 1,596 1,601 2,540 - -
Announcement Date 30/03/22 07/03/23 01/04/24 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 40.65L
17.13x6.55x12.55x1.74% 6.56TCr
32.67x8.73x28.87x0.07% 6.04TCr
38.83x6.91x20.67x0.84% 5.58TCr
44.13x6.17x29.36x-.--% 4.7TCr
34.55x3.29x14.19x-.--% 4.36TCr
-19.98x53.61x-21.71x-.--% 3.61TCr
36.23x8.96x23.37x0.36% 3.67TCr
41.91x8.08x27.1x-.--% 3.29TCr
-74.98x14.21x-76.38x-.--% 2.7TCr
Average 16.72x 12.95x 6.45x 0.33% 4TCr
Weighted average by Cap. 21.75x 11.58x 11.42x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Alaunos Therapeutics, Inc.

Historical PBR trend

Valuation ratios - PBR - Alaunos Therapeutics, Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Alaunos Therapeutics, Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Alaunos Therapeutics, Inc.

  1. Stock Market
  2. Stocks
  3. TCRT Stock
  4. Valuation Alaunos Therapeutics, Inc.